News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BioPartners Holdings AG: Clinical Phase III Trial Data Demonstrate Valtropin®'s Safety and Efficacy


8/14/2007 8:38:55 AM

BAAR, Switzerland--(BUSINESS WIRE)--In a significant development for the emerging field of biosimilars, Biopartners’ recombinant human growth hormone (rhGH) - Valtropin® - has demonstrated equivalent safety and efficacy to its reference product. This welcomed communication follows some concerns raised by established biopharmaceutical companies about the safety of biosimilars.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES